phase growth with subinhibitory concentrations of clindamycin, lincomycin, or pirlimycin was more susceptible to killing by PMLs than untreated bacteria. No effect on phagocytic killing was found when S. arrreus was pretreated with spectinomycin, 6'-n-propylspectinomycin, or gentamicin. The S. aureus remained resistant to serum lysis despite antibiotic treatment.
In contrast, spectinomycin and 6'-n-propylspectinomycin as well as clindamycin dramatically increased the susceptibility of E. coli to serum lysis (>99% destroyed).
Moderate killing of E. coli by PMLs was also found.
Antibiotics at subinhibitory concentrations (sub-MICS) are capable of altering bacterial morphology, growth rate, toxin production, surface antigens, and adhesion to mucosal surfaces1~10).
These alterations can affect the invasiveness of bacteria making them more susceptible to host defenses.
A cooperative interaction between antibiotics and host defense mechanisms could explain why certain antibiotics exhibit greater efficacy in vivo than predicted from their in vitro bioactivities. Thus a better understanding of antimicrobial activity in vivo might be obtained through the investigation of these interactions. Phagocytosis by polymorphonuclear leukocytes (PMLs) and serum lysis are two primary host responses for eliminating bacteria.
In the present study, the effects of sub-MIC levels of lincosaminide and spectinomycin related antibiotics on the susceptibility of bacteria to these two mechanisms were investigated. Leukocyte Preparation PMLs were purified from sodium citrate treated (0.4%) human venous blood by dextran sedimentation. The leukocytes were washed twice using low speed centrifugation in HBSS/HEPES and diluted to I x 107 leukocytes per ml in HBSS/HEPES containing 10 % autologous serum.
Assay Protocol for S. aureus Phagocytosis or serum lysis of S. aureus was determined as follows. Washed bacteria (0.5 ml), treated with antibiotic or untreated, were incubated with either 0.5 ml of serum (10-100%) or 0.5 ml of the leukocytes. The resulting suspension was mixed slowly by rocking for 45 minutes at 37° in a sterile NUNC cryotube (90 x 12.5 mm). Duplicate tubes were run of each different mixture tested. Colony forming units present in the suspensions were determined before and after incubation.
The samples taken at 0 and 45 minutes were diluted 1: 3 with normal saline and frozen. After thawing, the suspensions were subjected to mild sonic disruption for 5 seconds using a Branson Sonic Oscillator at a power setting of 1. This exposure was sufficient to lyse any remaining intact PMLs and to disrupt clumps of S. aureus without killing the bacteria. To quantify the surviving bacteria, each mixture was then diluted in ten-fold increments using normal saline. Two-tenths ml of each dilution was plated onto Trypticase soy agar. Following overnight incubation at 37°C, colony counts were made. Duplicate sets of plates were prepared for each sample and the results averaged.
Assay Protocol for E. coli When E. coli was used as the test organism, the assay was performed as described without the freezing and sonication steps. After incubation, the samples were diluted with saline and the viable bacteria were quantified immediately. These E. coli do not survive within leukocytes, therefore, lysing the PMLs was not necessary. No change in viable counts occurred after sonic disruption of the leukocytes.
MIC Determination
Since the S. aureus and E. coli were grown under very specific conditions for these assays, the MIC of each antibiotic vs. these organisms was determined using the same conditions. The MIC values obtained are shown in Table 1 . For the assays, the subinhibitory level of antibiotic which was added to the bacterial cultures still allowed a rate of growth similar to untreated cultures. A difference of <1 log in bacterial titers between control and antibiotic treated cultures was considered acceptable. No gross morphological changes in the antibiotic treated bacteria were obvious microscopically.
Results

Susceptibility
of Untreated Bacteria to Serum and PMLs Serum Susceptibility
Both the S. aureus and E. coli were tested for their sensitivity to human serum. Bacteria were grown as described and the assays were performed with serum concentrations ranging from 10-100 %. No PMLs were added. Both strains of bacteria were totally resistant to even full strength serum.
In fact, increases in bacterial titer of approximately 1.5-3-fold were observed within the 45-minute incubation. The bacteria remained resistant to serum through their entire growth cycle.
Leukocyte Susceptibility
The growth phase of bacteria has been reported to affect their susceptibility to phagocytosis11).
Therefore, bacteria were harvested at different times during log and stationary growth. The bacteria from each time period were mixed with PMLs and assayed as described. As shown in Table 2 , E.
coli was resistant to PML killing during its entire growth cycle. Bacterial cells from log phase cultures grew in the PML suspension during the 45-minute incubation. Although growth did not occur with bacterial cells from 18-hour cultures, these bacteria were still not susceptible to PMLs. PML killing of S. aureus, however, was very dependent upon the stage of growth of the bacteria when harvested.
The staphylococci became susceptible to PMLs in the late stages of log phase growth with the greatest susceptibility occurring with old stationary phase cultures. S. aureus was very resistant to phagocytic killing during early to mid-log phase growth. Total killing of the S. aureus was not found since this strain is capable of survival with PMLs. For comparing antibiotic treated and untreated bacteria, cultures from the end of log phase growth (4.5-j 5 hours) were routinely utilized. or gentamicin were destroyed by phagocytosis which was identical to that observed for untreated bacteria. These results are summarized in Table 4 . This particular pathogenic strain of E. coli (UC 9451) is resistant to lysis by serum components.
Gram-negative bacteria can be very susceptible to serum lysis, however. Therefore, antibiotics might be capable of altering the susceptibility of a serum resistant strain such as the one utilized. The E.
coli was grown in subinhibitory levels of clindamycin, the spectinomycins, and gentamicin. The serum killing assay was performed as described with varying concentrations of serum diluted in HBSS/HEPES.
Significant differences in serum susceptibility were found following antibiotic treatment as seen in Table   5 . Very little effect was detectable even in full strength serum when E. coli was grown in sub-MIC levels of gentamicin. However, upon exposure to sub-MIC levels of clindamycin, spectinomycin, or 6'-n-propylspectinomycin, >99% of the E. coli was destroyed by serum lysis. This effect was concentration dependent with over 50 % killing occurring with serum concentrations < 10 %.
Leukocyte Killing PML preparations were routinely made with 10% serum as the source of opsonins. Since serum killing of E. coli was still found at this level, controls containing only serum and bacteria were run with each antibiotic tested.
Killing by PMLs was considered to be the difference in viable counts between mixtures containing only serum and those containing serum plus PMLs.
As shown in Table 6 , phagocytosis was observed after treatment with clindamycin, spectinomycin, and 6'-n-propylspectinomycin. 
Discussion
These studies, along with others12~16), indicate that at low levels antibiotics can produce changes in bacteria which increase their susceptibility to host defense mechanisms in vitro. The effects observed were brought about by alteration of the bacteria, since all antibiotics were removed before exposure of the bacteria to serum or PMLs.
These changes did not affect the viability of the bacteria, but did increase their susceptibility to host defenses. The mechanisms involved appear to vary depending on the specific microorganisms and antibiotic involved. Clindamycin, and the other lincosaminides, were the only antibiotics tested which were effective in increasing the susceptibility of both S. aureus 502A and E. coil UC 9451 to phagocytic destruction by PMLs.
Although not dramatic, the increases in killing from 10-j60% were in the range reported in other studies17~20). Spectinomycin and its analog, 6'-n-propylspectinomycin, were not effective against S. aureus, but did have limited effectiveness against E. coli. An increase in PML killing of approximately 15 % was found.
None of the antibiotics tested were capable of altering the serum resistance of the S. aureus. However, significant changes in serum sensitivity were found after exposure of the E. coli to clindamycin, spectinomycin, and 6'-n-propylspectinomycin. Untreated E. coli were totally resistant to serum, whereas, 99% of those grown in the presence of subinhibitory levels of these antibiotics were killed in 20% serum. Gentamicin had no effect against either the S. aureus or the E. coli and served as a negative control. These results are consistent with other reports involving gentamicin11,21,22) Augmentation of host defense mechanisms by antibiotics could explain discrepancies between in vivo efficacy and in vitro bioactivities. It could also explain why therapeutic effects can be obtained even when the serum levels of some antibiotics fall below their MIC. Thus, assays which measure modulation of host defense mechanisms, such as the one described, may prove useful as early indicators of in vivo efficacy. Although the clinical significance of these observations remains to be established, investigation of synergistic effects between antibiotics and host defense mechanisms should provide a better understanding of the potential antimicrobial action of antibiotics in vivo.
